Therapeutics: Adenosine A2B receptor (ADORA2B); cytotoxic T-lymphocyte associated protein 4 (CTLA4; CD152); programmed cell death 1 (PD-1; PDCD1; CD279)

Cancer

INDICATION: Breast cancer; melanoma

Patient sample, cell culture and mouse studies suggest inhibiting ADORA2B could help treat metastatic breast cancers and metastatic melanoma.

Read the full 226 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE